Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02411448
Title A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company

lung non-small cell carcinoma



Gefitinib + Ramucirumab

Erlotinib + Ramucirumab

Osimertinib + Ramucirumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

No variant requirements are available.